Ligand Pharmaceuticals Incorporated (LGND)
LGND Stock Price Chart
Explore Ligand Pharmaceuticals Incorporated interactive price chart. Choose custom timeframes to analyze LGND price movements and trends.
LGND Company Profile
Discover essential business fundamentals and corporate details for Ligand Pharmaceuticals Incorporated (LGND) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Nov 1992
Employees
68.00
Website
https://www.ligand.comCEO
Todd C. Davis
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
LGND Financial Timeline
Browse a chronological timeline of Ligand Pharmaceuticals Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $1.97, while revenue estimate is $58.71M.
Earnings released on 7 Aug 2025
EPS came in at $1.60 surpassing the estimated $1.54 by +3.90%, while revenue for the quarter reached $47.63M , missing expectations by -9.85%.
Earnings released on 8 May 2025
EPS came in at $1.33 surpassing the estimated $1.30 by +2.31%, while revenue for the quarter reached $45.33M , beating expectations by +2.32%.
Earnings released on 27 Feb 2025
EPS came in at -$1.64 falling short of the estimated $1.37 by -219.71%, while revenue for the quarter reached $42.81M , beating expectations by +21.26%.
Earnings released on 7 Nov 2024
EPS came in at -$0.39 falling short of the estimated $0.75 by -152.00%, while revenue for the quarter reached $51.81M , beating expectations by +32.81%.
Earnings released on 6 Aug 2024
EPS came in at $1.40 surpassing the estimated $1.10 by +27.27%, while revenue for the quarter reached $41.53M , beating expectations by +26.39%.
Earnings released on 7 May 2024
EPS came in at $1.20 surpassing the estimated $1.13 by +6.19%, while revenue for the quarter reached $30.98M , beating expectations by +10.95%.
Earnings released on 27 Feb 2024
EPS came in at $1.05 surpassing the estimated $0.58 by +81.03%, while revenue for the quarter reached $28.10M , beating expectations by +9.26%.
Earnings released on 8 Nov 2023
EPS came in at $1.02 surpassing the estimated $0.68 by +50.00%, while revenue for the quarter reached $32.87M , beating expectations by +20.88%.
Earnings released on 8 Aug 2023
EPS came in at $1.42 surpassing the estimated $0.76 by +86.84%, while revenue for the quarter reached $26.37M , beating expectations by +2.47%.
Earnings released on 4 May 2023
EPS came in at $2.28 surpassing the estimated $0.89 by +156.18%, while revenue for the quarter reached $43.98M , beating expectations by +29.20%.
Earnings released on 22 Feb 2023
EPS came in at $1.36 surpassing the estimated $1.23 by +10.57%, while revenue for the quarter reached $50.38M , beating expectations by +14.27%.
Earnings released on 7 Nov 2022
EPS came in at $0.41 falling short of the estimated $0.45 by -8.89%, while revenue for the quarter reached $66.09M , beating expectations by +72.45%.
Stock split effective on 2 Nov 2022
Shares were split 1603 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Aug 2022
EPS came in at $0.34 falling short of the estimated $0.54 by -37.04%, while revenue for the quarter reached $57.42M , beating expectations by +52.16%.
Earnings released on 4 May 2022
EPS came in at $0.58 falling short of the estimated $0.61 by -4.92%, while revenue for the quarter reached $45.69M , beating expectations by +33.57%.
Earnings released on 17 Feb 2022
EPS came in at $1.80 surpassing the estimated $1.38 by +30.43%, while revenue for the quarter reached $72.47M , beating expectations by +11.35%.
Earnings released on 9 Nov 2021
EPS came in at $1.58 surpassing the estimated $1.02 by +54.90%, while revenue for the quarter reached $64.84M , beating expectations by +21.71%.
Earnings released on 29 Jul 2021
EPS came in at $1.63 surpassing the estimated $1.36 by +19.85%, while revenue for the quarter reached $84.68M , beating expectations by +20.12%.
Earnings released on 3 May 2021
EPS came in at $1.41 surpassing the estimated $1.13 by +24.78%, while revenue for the quarter reached $55.15M , missing expectations by -12.46%.
Earnings released on 3 Feb 2021
EPS came in at $1.62 surpassing the estimated $1.07 by +51.40%, while revenue for the quarter reached $69.99M , beating expectations by +11.11%.
Earnings released on 30 Oct 2020
EPS came in at $1.04 falling short of the estimated $1.06 by -1.89%, while revenue for the quarter reached $41.85M , beating expectations by +6.12%.
LGND Stock Performance
Access detailed LGND performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.